These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1056 related items for PubMed ID: 18163551

  • 1. Novel prodrugs of tegafur that display improved anticancer activity and antiangiogenic properties.
    Engel D, Nudelman A, Tarasenko N, Levovich I, Makarovsky I, Sochotnikov S, Tarasenko I, Rephaeli A.
    J Med Chem; 2008 Jan 24; 51(2):314-23. PubMed ID: 18163551
    [Abstract] [Full Text] [Related]

  • 2. Novel phosphonium salts display in vitro and in vivo cytotoxic activity against human ovarian cancer cell lines.
    Manetta A, Gamboa G, Nasseri A, Podnos YD, Emma D, Dorion G, Rawlings L, Carpenter PM, Bustamante A, Patel J, Rideout D.
    Gynecol Oncol; 1996 Feb 24; 60(2):203-12. PubMed ID: 8631539
    [Abstract] [Full Text] [Related]

  • 3. Comparison of the pharmacological profile of an olivacine derivative and a potential prodrug.
    Kraus-Berthier L, Guilbaud N, Léonce S, Parker T, Genissel P, Guillonneau C, Goldstein S, Atassi G, Pierré A.
    Cancer Chemother Pharmacol; 2002 Aug 24; 50(2):95-103. PubMed ID: 12172972
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
    Hoch U, Lynch J, Sato Y, Kashimoto S, Kajikawa F, Furutani Y, Silverman JA.
    Cancer Chemother Pharmacol; 2009 Jun 24; 64(1):53-65. PubMed ID: 18931998
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Structure-activity relationships of C-17 cyano-substituted estratrienes as anticancer agents.
    Leese MP, Jourdan FL, Gaukroger K, Mahon MF, Newman SP, Foster PA, Stengel C, Regis-Lydi S, Ferrandis E, Di Fiore A, De Simone G, Supuran CT, Purohit A, Reed MJ, Potter BV.
    J Med Chem; 2008 Mar 13; 51(5):1295-308. PubMed ID: 18260615
    [Abstract] [Full Text] [Related]

  • 8. Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5- methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan- 2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor.
    Bhide RS, Cai ZW, Zhang YZ, Qian L, Wei D, Barbosa S, Lombardo LJ, Borzilleri RM, Zheng X, Wu LI, Barrish JC, Kim SH, Leavitt K, Mathur A, Leith L, Chao S, Wautlet B, Mortillo S, Jeyaseelan R, Kukral D, Hunt JT, Kamath A, Fura A, Vyas V, Marathe P, D'Arienzo C, Derbin G, Fargnoli J.
    J Med Chem; 2006 Apr 06; 49(7):2143-6. PubMed ID: 16570908
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. CGP 48664, a new S-adenosylmethionine decarboxylase inhibitor with broad spectrum antiproliferative and antitumor activity.
    Regenass U, Mett H, Stanek J, Mueller M, Kramer D, Porter CW.
    Cancer Res; 1994 Jun 15; 54(12):3210-7. PubMed ID: 8205541
    [Abstract] [Full Text] [Related]

  • 11. Thrombospondin-1 mimetic peptide inhibitors of angiogenesis and tumor growth: design, synthesis, and optimization of pharmacokinetics and biological activities.
    Haviv F, Bradley MF, Kalvin DM, Schneider AJ, Davidson DJ, Majest SM, McKay LM, Haskell CJ, Bell RL, Nguyen B, Marsh KC, Surber BW, Uchic JT, Ferrero J, Wang YC, Leal J, Record RD, Hodde J, Badylak SF, Lesniewski RR, Henkin J.
    J Med Chem; 2005 Apr 21; 48(8):2838-46. PubMed ID: 15828822
    [Abstract] [Full Text] [Related]

  • 12. ZD6126: a novel vascular-targeting agent that causes selective destruction of tumor vasculature.
    Davis PD, Dougherty GJ, Blakey DC, Galbraith SM, Tozer GM, Holder AL, Naylor MA, Nolan J, Stratford MR, Chaplin DJ, Hill SA.
    Cancer Res; 2002 Dec 15; 62(24):7247-53. PubMed ID: 12499266
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Antiangiogenic potency of various chemotherapeutic drugs for metronomic chemotherapy.
    Drevs J, Fakler J, Eisele S, Medinger M, Bing G, Esser N, Marmé D, Unger C.
    Anticancer Res; 2004 Dec 15; 24(3a):1759-63. PubMed ID: 15274352
    [Abstract] [Full Text] [Related]

  • 15. Antitumor agents 253. Design, synthesis, and antitumor evaluation of novel 9-substituted phenanthrene-based tylophorine derivatives as potential anticancer agents.
    Wei L, Shi Q, Bastow KF, Brossi A, Morris-Natschke SL, Nakagawa-Goto K, Wu TS, Pan SL, Teng CM, Lee KH.
    J Med Chem; 2007 Jul 26; 50(15):3674-80. PubMed ID: 17585747
    [Abstract] [Full Text] [Related]

  • 16. Antitumor activity of imidazothioxanthones in murine and human tumor models in vitro and in vivo.
    Varvaresou A, Iakovou K, Gikas E, Fichtner I, Fiebig HH, Kelland LR, Double JA, Bibby MC, Hendriks HR.
    Anticancer Res; 2004 Jul 26; 24(2B):907-19. PubMed ID: 15161044
    [Abstract] [Full Text] [Related]

  • 17. EPOX inhibits angiogenesis by degradation of Mcl-1 through ERK inactivation.
    Sun HL, Tsai AC, Pan SL, Ding Q, Yamaguchi H, Lin CN, Hung MC, Teng CM.
    Clin Cancer Res; 2009 Aug 01; 15(15):4904-14. PubMed ID: 19622586
    [Abstract] [Full Text] [Related]

  • 18. (R,R)-2,2'-[1,2-ethanediylbis[imino(1-methyl-2,1-ethanediyl)]]- bis[5-nitro-1H-benz[de]isoquinoline-1,3-(2H)-dione] dimethanesulfonate (DMP 840), a novel bis-naphthalimide with potent nonselective tumoricidal activity in vitro.
    Kirshenbaum MR, Chen SF, Behrens CH, Papp LM, Stafford MM, Sun JH, Behrens DL, Fredericks JR, Polkus ST, Sipple P.
    Cancer Res; 1994 Apr 15; 54(8):2199-206. PubMed ID: 8174127
    [Abstract] [Full Text] [Related]

  • 19. Formaldehyde-releasing prodrugs specifically affect cancer cells by depletion of intracellular glutathione and augmentation of reactive oxygen species.
    Levovich I, Nudelman A, Berkovitch G, Swift LP, Cutts SM, Phillips DR, Rephaeli A.
    Cancer Chemother Pharmacol; 2008 Aug 15; 62(3):471-82. PubMed ID: 18030472
    [Abstract] [Full Text] [Related]

  • 20. Preclinical antitumor activity of the oral platinum analog satraplatin.
    Wosikowski K, Lamphere L, Unteregger G, Jung V, Kaplan F, Xu JP, Rattel B, Caligiuri M.
    Cancer Chemother Pharmacol; 2007 Sep 15; 60(4):589-600. PubMed ID: 17541592
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 53.